Podcasts about what dean

In today’s episode of the As Told by Nomads Podcast, join me and my guest, Dean Foster, as we talk about how cultural awareness can improve global work interactions. Dean Foster is a speaker, presenter, and author, who has played a central role in developing cross-culture training and consulting. He is also the founder of DFA Intercultural Global Solutions and the former worldwide director of Berlitz Cross-Cultural. Currently, Dean serves as the executive strategic consultant of Dwellworks Intercultural, helping people develop global cultural agility and a skillset for working across borders. Now, if you want to be more culturally aware, feel free to get in touch with Dean Foster via his website down below!Cultural Awareness In Global Virtual WorkWith how global work has become, cultural awareness can significantly affect how we communicate with our clients and our team. After all, cultures often differ in communication styles. Some cultures would evade negatives and retreat into silence rather than elect a topic. Meanwhile, others would come forward with a case and explain issues in detail. A global meeting will always have people with varying communication styles, and having it in a virtual setting will only accentuate these differences even more. Hence, as a leader or even a member of a global meeting, whether virtual or not, you need to practice mindfulness, understanding, and respect, all essential in cultural awareness. That way, people can feel comfortable communicating the way they need to. You have to use virtual meetings as a vehicle for listening, not just telling, and it takes enlightenment from the right resources to do so, such as Cultural Concierge. Outline of the episode:[04:07] Dean Foster’s background and how he got to where he is today.[08:48] What changed in globalization and cross-cultural work through the years.[16:30] How the revolution in technology supercharged the influence of cultural information and training.[18:34] What Cultural Concierge is and how technology made it easier for the service to provide ongoing cross-cultural support.[20:51] How cultural awareness can solve the fundamental issues of working globally.[25:13] Being guided by a cultural expert versus doing the research yourself.[27:13] The best practices for remote work and how to improve communication in a virtual setting.[32:17] How Dean navigated between his media and teaching career through storytelling.[35:50] Cultural Dexterity versus Cultural Relativity: how understanding and respect is essential in working globally.[40:07] What Dean thinks is the future of virtual work based on life during the pandemic.[41:53] The element of loneliness in the relocation business and how to get comfortable with separation from familiarity.[45:42] How Dean Foster uses his difference to make a difference.Resources:LinkedInWebsiteCultural Concierge Services:UYD Collective:Connect with Tayo Rockson and the As Told By Nomads Podcast on:Linkedin:PodcastTwitter:Personal Website See acast.com/privacy for privacy and opt-out information.

In this GYDA Talks, Robert talks to Dean Seddon of Maverrik. Dean founded Maverrik in 2013 as a consultancy and business development company. Having delivered growth in several small and large businesses, he embarked on building an organisation which would help business cut through the fog and grow people, sales and profit.Dean is a practical, hands-on business speaker and trainer. Supported by the Maverrik team, Dean speaks at over 100 events per year, consults with large and small businesses across the world and is passionate about getting results for people. Robert and Dean discuss:What Dean and Maverrik doHow did you get to 2020? The journey.Utilising LinkedIn as a sales toolHow can agencies use it on behalf of their clients… any examples…?What are the clever things we can do with LI? How can it be embedded or linked into a bigger campaign… any examples…?And what of LI advertising… examples…? Can it be compared pound for pound with Google or Facebook advertising?DIY or can a Done For You service actually work?What next for DeanTop tips … for other agency owners This is a bitesize video of the full hour-long interview with Garry. To watch the rest visit GYDA Member Hub!

Dean Pohlman is an E-RYT 200 certified yoga instructor and the founder of Man Flow Yoga. Dean is widely considered to be an authority on Yoga for Men. He has worked with physical therapists to create yoga programs for back health and spinal recovery. His workouts and programs have been used by professional and collegiate athletes, athletic trainers, and personal trainers; and have been recommended by physical therapists, doctors, chiropractors, and other medical professionals. Dean is a successfully published author through DK Publishing (Yoga Fitness for Men), selling 35,000 copies worldwide in English, French, and German; in addition to being a co-producer of the Body by Yoga DVD Series, which has sold over 40,000 copies on Amazon since its release in 2016. Man Flow Yoga has been featured in Muscle & Fitness Magazine, Mens' Health, The Chicago Sun, New York Magazine, and many more major news media outlets. For more resources to uncover your innate super powers as a Secret Yogi check out http://www.secretyogisociety.com/ (www.secretyogisociety.com) Instagram: https://www.instagram.com/secret_yogi/ (https://www.instagram.com/secret_yogi/) Facebook: https://www.facebook.com/secretyogisociety/ (https://www.facebook.com/secretyogisociety/) We want to hear from you! So don't forget to rate, review and subscribe! 04:39 – Is yoga for everyone? Dean's story from athlete to finding yoga and starting Man Flow Yoga Quote: “Have you ever tried to get a 55year old man to get to go toa yoga class. Primarily filled with 20 year old women & had him do a forward fold. Tell that guy yoga is for everyone” Quote: “Anything that doesn't hurt your body but challenges your body is a great workout” Quote: “Mainly to show guys. Hey, yoga is cool. This is a great workout. This is going to help you get stronger” 14:00 – Dean started to put fitness focused yoga videos on YouTube and the response he got morphed into his company today called Man Flow Yoga, which makes yoga assessable to so many people that would of never experienced yoga how it is traditionally taught. Quote: “Initially I thought I was going to be attracting college athletes who were like ‘I'm in really good shape & I want to get in better shape' but the type of people I was really attracting were guys who were in their 40s, 50s, 60s. Guys who thought other workouts weren't going to work for them & heard yoga is gentler & maybe it can do something for me.” 20:00 – Practicing and teaching mindfulness. Walk the talk… "We all have our own definitions of what a yoga pose, or asana, is. How I share it on this show it is any movement that fuses breath, mindfulness, and awareness. May that be your own style of yoga unique to you or a traditional lineage of asana practices like Iyengar, Ashtanga and so on. It's a moving meditation and the traditional poses were designed to remove physical tension to better meditate may that be sedentary or a moving meditation to realize we have all that we need within." 22:00 – We discuss Dean's article “https://manflowyoga.com/blog/5-major-problems-of-traditional-yoga/ (5 Problems Why Traditional Yoga Is Bad: And The Fixes)” Quote: “The reason why so many people like yoga & the myriad of benefits that are listed from it like lowering your blood pressure, reducing stress, improving your sleep, helping you be more mindful. That happens at the intersection of movement, body awareness, and breathing. So that's the most important part.” 30:00 – Dean shares his students experience from teaching revolving around people doing what they physically enjoy without pain. Than we dive into the bigger picture of achieving your physical goals through yoga and what it truly takes.  31:15 – What Dean & I have found from only doing yoga as our sole form of fitness. Is a traditional yoga enough? 43:15 – Do you think your too inflexible for yoga? Listen to Dean's advice… Resource: http://manflowyoga.com/free... Support this podcast

Dean Holland created one of the first coaching programs we went through online and he’s been into creating info products and affiliate marketing for many years. He also has a book about affiliate marketing called The Iceberg Effect which you can get for free. On today’s show, you’ll get to hear Dean’s evolution which ties into a really solid affiliate system and where he also is helping a ton of people selling online.    We reminisce about the early days of affiliate promotions all the way to what is working current day, and how Dean has found the perfect blend for his business of promoting his own offers with other marketer’s products which are a good fit for his audience, as well as some change in thinking over the years in regards to how he markets to the leads he gets. After you get your mind reeling with the possibilities, check out our other episodes with Navid Moazzez and our Therapy Session show we did earlier this year where we discuss more affiliate marketing strategies, what most affiliate marketers are doing wrong, and how to set yourself apart from the rest.  “I just came around to the viewpoint that if there is a complimentary software or something that I know can help my customers...why can't I be the one to provide that solution and everybody wins.” - Dean Holland Some Topics We Discussed Include: We reminisce about our own early days in the affiliate marketing game, even recalling who was our very first customer was (you’ll never guess!) How Dean’s wife actually beat his conversions even with an ugly funnel Why recommending other people’s product to your list actually increases the sales of your own What Dean is doing with his best performing broadcast emails The four most important things to focus on daily, which have a direct impact on revenue Dean’s observation with working with newcomers and the key things to get you moving towards your first sale And much, much more! Contact Dean Holland: The Iceberg Effect References and Links Mentioned: ClickFunnels The Iceberg Effect Just The Tips podcast Dream 100 list Ready, Fire, Aim by Michael Masterson Fix This Next any other books by Mike Michalowicz FlowchartGroup.com - be sure to hop in our Facebook group to chat with us, our other amazing guests that we’ve had on the show, and fellow entrepreneurs! Are you ready to be EPIC with us?! Then grab our EGP Letter here! This episode is sponsored by our go-to SEO research tool, Ahrefs.com, by Easy Webinar and Gina Horkey’s Podcast Production School. Therapy Session – Unapologetic Affiliate Marketing Strategies Affiliate Marketing Using Virtual Summits - Navid Moazzez

Jay Abraham, Dean Jackson, and Joe Polish share perspectives for leading a business in the midst of worldwide chaos, uncertainty, and fear.  If you’d like access to the show notes, a direct play link, or the exercise to help you take action on what was discussed, please visit http://www.ilovemarketing.com/362. Here’s a glance at what you’ll learn from Jay, Dean, and Joe in this episode:  The difference between CHAOS-INSPIRED exploitation and opportunity. What they think of Coronavirus and its impact on the market RIGHT NOW. How Jay and his client got out of massive financial devastation.  Why there’s ALWAYS a solution - even in adversity.  What Dean did in 2008 to leverage an ethical opportunity. What it looks like to respond versus react. The ONE practice that permanently changed the way Joe responds to life.  B.R.A.N.D.: A Buying Reflex Affecting NOW Decisions. How to be PREEMPTIVE and ELEVATE yourself above the chaos.  Why a RESULTS-LEADER will always trump a thought-leader.  The DISCONNECT between the value you sell and the value someone will buy. The incorrect ASSUMPTION entrepreneurs make about results.  How Dean adapted quickly to Coronavirus limitations to STILL produce results.  Unlearning is more important than learning at some point.  FOUR questions to ask yourself during your designated “thinking-time”.

This week Dr. Don travels back across the pond to the oasis-like town of Marlow, Buckinghamshire, England to speak with Chiropractor Dr. Dean Rieder. Just three years ago, Dr. Rieder graduated from Durbin Chiropractic College in South Africa. He moved to the UK to start his practice and during this episode shares the ups and downs of attracting practice members, the costs of starting anew, and his unique approach to a homemade commercial with a famous client. Dr. Rieder thirstily seeks out any and all seminars, including the Vitality Shift program, and podcasts about chiropractic care. He recommends taking action as opposed to overthinking. And, due to his recommendation, the next shift unplugged event will be held in Marlow in September. After listening to this episode, you will have a better understanding of the trials and tribulations new chiropractors face, the requirements for practicing abroad, and why it is important to get involved with a chiropractic community. Key Takeaways: ● Dean studied at Durbin Chiropractic College in South Africa and then moved to England to start his practice. [2:14] ● How Dean discovered Vitalistic Chiropractic and the education he sought out after graduating. [8:00] ● What Dean did to get his name out there and gain practice members. [12:11] ● Dean visits the countryside and exercises as a form of self-care. [14:33] ● Dean shares his Vitality Shift experience and how his chiropractic care has changed over time. [19:31] ● Dean shares a story about the day Russell Brand came into his office and the video they made together. [24:27] ● Dean’s advice for chiropractors is to listen to chiropractic podcasts and to get involved with your community. [32:12] ● The next Shift Unplugged will be the first week of September in Marlow, UK. [35:18]   Learn More: Halsa Group Vitality Shift Website True Concept Seminars Dr. Don MacDonald @DrDonMacDonald on Twitter

Reflecting on the past is one of the best ways to plan for the future. Dean and I always take the time after Christmas to reflect on the previous year and set goals for the next. There are four questions we use to reflect, that drive the upcoming week, month, quarter, and year. To learn our strategy (and how we feel 2019 fared) listen to this episode of Just the Tips! Outline of This Episode [2:20] Starting the new year off right [4:00] Planning for an entire year is unrealistic [7:15] Focus on what went right and celebrate [9:30] Double-down on your strengths [12:30] How to structure your team meetings [17:50] Strategic planning activities [19:15] What James did right in 2019 [22:15] What Dean is proud of from 2019 [25:50] 4 Questions to guide the process [26:20] What could’ve been better for James? [28:50] What could’ve been better for Dean? [31:00] Planning, reflection, and course-correction Why an annual plan is unrealistic I’ll be honest, there needs to be a little give and take when you try and make a plan for the upcoming year. Time is complex and there is no way to truly foresee what could happen. Things will be thrown your way that you can’t prepare for. So make sure as you’re planning your expectations aren’t too rigid.  Incorporate a measure of dynamic flexibility in your planning. Control what you can, but plan for the unexpected. Dean spent a chunk of his year working on his book—that he’s FINALLY completed—but didn’t expect the level of disasters that were thrown his way. What came up shifted his timeline, but he still accomplished what he set out to do.  A strengths-based approach is always the right move I firmly believe that you need to stop focusing on improving your weaknesses. You will make the biggest strides in your life and business when you focus on your strengths and double down on what is working. You can go from being great at something to being the best.  Wouldn’t you rather accomplish greatness instead of only becoming slightly less-than-mediocre at your weakness?  We all have a superpower. Something that we excel at and do like no one else. So mitigate your weakness and stay in your zone of genius. Identify the strengths in others and build a team that leverages their strengths to make up for your weaknesses. How to structure reflective team meetings First of all, there is power in recognizing the fact that you cannot always be the smartest person in the room. It is beneficial to get input from 100% of your staff so you can hear everyone’s perspective about your year.  I typically structure it by making a list of the questions I want my team to think over before the meeting. It gives them time to reflect and not put them on the spot. This allows for a more conversational—and less stressful—meeting.  Above all, it’s important that everyone feels like they have a voice and that they’re contributing to the ongoing vision of the business. The meeting is extremely valuable for team-building and goal-setting. Keep listening to hear what our big wins were this year, and where we missed the mark and want to improve in 2020.  The 4 questions that help you reflect on the past year There are 4 questions that we use to help guide the process both personally and in our businesses: What went really well? What am I proud of? What could’ve been better? What do we need to do more of? What do we need to do less of? If you continue to ask yourself these questions consistently, you’ll start to catch issues before they go too far. You’ll limit your risk. If you’re not constantly course-correcting as you are carrying out your plan for the year, you won’t reach your destination.  The planning and reflection cycle can make a world of difference. Listen to the whole episode as Dean and I walk through the process. Resources & People Mentioned Hiring Like a Boss Managing Like a Boss The Iceberg Effect: coming soon! Musicfor “Just The Tips” is titled, “Happy Happy Game Show” by Kevin MacLeod (http://incompetech.com) Licensed under Creative Commons: By Attribution 3.0 License Connect With James and Dean James P. Friel: CEO Quickstart: https://jamespfriel.com/ceo-quickstart/ Facebook Group: https://www.facebook.com/groups/hustledetox/ Site: www.jamespfriel.com Interested in being a guest on the show? Dean Holland: Blog: www.DeanHolland.com FB Page: https://www.facebook.com/DeanHollandHQ Billion Dollar Project: https://www.facebook.com/groups/BillionDollarProject/ Audio Production and Show notes by PODCAST FAST TRACK https://www.podcastfasttrack.com

On today’s episode of Just the Tips, we peel back the layers on the mystery, wrapped in an enigma, that is Dean Holland. I’ve known Dean for years and if you asked me what it is that Dean does, I couldn’t tell you. But over a recent visit, I realized what Dean’s superpower is: Creating affiliate programs so businesses don’t have to rely on paid traffic. That’s a bona fide superpower, and on today’s episode we dive into how Dean does it. Dean Holland: An Origin Story Dean has sold over $10 million in products online, and only just recently began using paid traffic. I think that if Facebook went away tomorrow, Dean would be perfectly fine (although he’d be a little angry, because he just learned how to use Facebook ads). But how Dean got into entrepreneurship and business more generally was through affiliate marketing. And so he looked at his history as an affiliate marketer, and he said, “Okay, what do the vendors do that make it easier for me as an affiliate marketer?” And he just started building from there. Affiliate marketing brings you the traffic The very basis of having an affiliate program is to have an army of people out there, trying to drive traffic to your business. Affiliates don’t get paid unless a customer buys something, so it’s like having a sales army out there that’s only paid by commission. As Dean says, it’s almost the perfect traffic source. The only trouble is: You don’t own that traffic. You can’t control it. So how do you get the most out of it? The Bearded Wonder provides the answers. Build the highest-earning affiliate program you can The big lesson that Dean took away from being an affiliate marketer is that you have to create the best-paying sales process that you possibly can. Affiliates will go where the money is. If I’m an affiliate thing, and I have 10 different offers that all fit my audience, which one am I going to choose? It’s the one that makes me the most money. Often, affiliates measure their performance by earnings per click. And so an affiliate is going to choose your product every time, if you offer them greater earnings per click. How to keep someone as an affiliate When Dean first started creating affiliate programs, they would be based around a product launch. So there would be a large push for, say, seven days, and then the program would be done. Since then, he’s switched it up so that he has an affiliate platform, where he’s trying to build long-term relationships with his affiliates. And there are a variety of ways to do that, because no one is going to push your products every day to the same audience. But luckily, Dean has lived and breathed the affiliate life, so he knows how to make it work. Outline of This Episode [2:45] Dean’s superpower [4:47] Dean’s beginning as an affiliate marketer [8:52] What Dean learned and applied to his own business [12:56] Get your baseline before you approach affiliates [14:37] What are the affiliate models? [17:51] How Dean creates his affiliate program [22:00] Treating an affiliate like an exclusive partner Music for “Just The Tips” is titled, “Happy Happy Game Show” by Kevin MacLeod (http://incompetech.com) Licensed under Creative Commons: By Attribution 3.0 License Connect With James and Dean James P. Friel: CEO Quickstart Program: https://jamespfriel.clickfunnels.com/about-ceo-quickstart-program?utm_campaign=learnmore&utm_medium=aep&utm_source=homepage Facebook Group:https://www.facebook.com/groups/hustledetox/ Site: www.jamespfriel.com Interested in being a guest on the show? Dean Holland: Blog: www.DeanHolland.com FB Page: https://www.facebook.com/DeanHollandHQ Billion Dollar Project: https://www.facebook.com/groups/BillionDollarProject/

Monday Morning Radio Host Dean Rotbart confesses that he doesn’t know who his guest is on this week’s podcast.  It’s not that Dean doesn’t have a fascinating guest, or that the guest’s book – “Undistrupted: How Highly-Effective People Deal with Disruptions” – isn’t a valuable business read; it’s just that Dean literally does not know who wrote the book. The author, who lives in The Netherlands [Dean phoned him there], uses the pseudonym John Vespasian and has written ten books. What Dean also knows is that this week’s mystery guest is a well-read student of global history [think Russian industrialist Savva Mamontov (1841-1918), and 12th-century French statesman, Abbot Suger], and draws excellent insights from bygone eras that we all can apply to our lives today. So Dean assures us that his guest has plenty of good advice to dispense; he just doesn’t know who he’s talking to.   Illustration: The author known as John Vespasian Posted: May 6, 2019Monday Morning Run Time: 32:45

In this episode, Devi chats with Dean Smith about the life-transforming power of forgiveness.  Dean is a forgiveness expert and Certified Life & Leadership Coach. He was the subject of an award-winning documentary (Live To Forgive) that chronicles his journey from the debilitating murder of his mother to the monumental breakthroughs that have uniquely prepared him to teach and inspire audiences around the nation.  If you are dealing with an area of your life, where you are holding bitterness, resentment or non-forgiveness, this is an episode that you don’t want to miss. Devi & Dean discuss...  Dean's life-transforming journey of forgiveness Being adopted by a loving pastor after his mom died Dealing with addiction to drugs and alcohol Going to the very “bottom” to look “up” The moment of choice when Dean decided to forgive The gift of knowing that "You’ll never live in the fullness of your God-given potential until you have made forgiveness a priority" "Unshackling" from pain and bitterness The different aspects of forgiveness The significance of the last few moments before you go to sleep What is available in the absence of bitterness and non-forgiveness What Dean said to his mother’s killer when he spoke to him upon his release from jail (this may surprise you) The making of the documentary "Live to Forgive" One of the amazing conversations that took place when Dean met up with his mom’s murderer in person for the first time The two things that Dean did that started him down the path of forgiveness Making a choice, speaking it, and asking for help The freedom that comes from "making the choice to keep making the choice"  How bitterness and unforgiveness are like cyanide to your soul, keeping you from your full potential The new possibility that “I can forgive anyone, for anything” The two things that neuroscience has discovered that will move your brain most powerfully and how to use them to assist you in forgiveness: the words that you speak the pictures that you make in your mind Powerful steps towards forgiveness Why it is not always practical or appropriate to reconcile with the person that you choose to forgive How choosing to be a loving person doesn’t mean that you don’t have boundaries anymore Dean's journey of self-forgiveness Choosing to be a "victor" vs. a "victim" Taking the hardships of your life and turning them into a blessing for others and more…  Connect with Dean on his website @ deansmithcoaching.com On Facebook: https://www.facebook.com/deansmithcoachingOn YouTube:  https://www.youtube.com/channel/UC9q0yO5zlzZT6D915mmh2qQ To receive your FREE Gift from Dean text YEP to 38470 If you are outside of the US:  Email YEP to dean@deansmithcoaching.com More About Dean: With a diverse and extraordinary background in professional sports, entrepreneurialism, and high-end sales, Dean has dedicated his life through ministry, executive coaching and as a keynote speaker to transform and empower leaders to live and perform with passion and purpose. He is the founder/director of Live To Forgive Ministries and the President of Dean Smith Consulting Group, LLC. In addition to earning a Master’s degree in Organizational Leadership, Dean was given the highly coveted, ‘Class Clown’ award his senior year of high school.

Host Lisa Kiefer interviews Innovative Genomics Initiative lab member and UC Berkeley post-doc Mark DeWitt, PhD., about the perils and promise of the CRISPR-Cas9 gene editing technology.TRANSCRIPTSpeaker 1:You're listening to method to the madness at my weekly public affairs show, k a l x Berkeley Celebrating Bay area innovators. I'm your host, Lisa Kiefer, and today I'm going to be interviewing biophysicist Mark Dewitt. We'll be talking about gene editing, both Fitz promise and itch perils [00:00:30] as well as his work here at the innovative genomics initiative lab at the La coshing center for Genomic Engineering on the UC Berkeley campus. Welcome to the program, Mark. Thanks for having me. Speaker 2:You're a biophysicist a postdoc researcher at the innovative genomics initiative here on the UC Berkeley campus at the La cashing center for Genomic Engineering, and you're doing some exciting work on many [00:01:00] things and we're going to get into what you're doing. But before we do that, I want to talk about the golden age of gene editing and talk about some of the fundamental parts of that so that our listeners who are not scientists or biophysicists can understand what we're talking about. Here's UC Berkeley's very own professor Jennifer Doudna a few years ago with my colleague Emmanuel sharp on ta. I invented a new technology for editing genomes. It's called CRISPR cas nine the CRISPR technology [00:01:30] allows scientists to make changes to the DNA in cells that could allow us to cure genetic disease. The CRISPR technology came about through a basic research project that was aimed at discovering how bacteria fight viral infections. Speaker 2:Bacteria have to deal with viruses in their environment and we can think about a viral infection like a ticking time bomb. A bacterium has only a few minutes to diffuse the bomb before it gets destroyed. So many bacteria have in their cells [00:02:00] and adaptive immune system called CRISPR that allows them to detect viral DNA and destroy it. Part of the CRISPR system is a protein called cas nine that's able to seek out and cut and eventually degrade a viral DNA in a specific way, and it was through our research to understand the activity of this protein cas nine that we realize that we could harness its function as a genetic engineering technology, a way for scientists [00:02:30] to delete or insert specific bits of DNA into cells with incredible precision. The CRISPR technology has already been used to change the DNA in the cells of mice and monkeys. Other organisms as well. Chinese scientists showed recently that they could even use the CRISPR technology to change genes in human embryos and scientists in Philadelphia showed they could use CRISPR to remove the DNA of an integrated HIV virus Speaker 3:from [00:03:00] infected human cells. Okay. Mark, let's get a little bit more into this gene editing. Speaker 4:You can imagine that our genome is essentially like a document that has 3 billion letters. Those were the different bases in the DNA that makes up our genome, right? A 20,000 genes, 3 billion characters, which I think is about a million pages. This is an, if it was an award document, I think that would be about three gigabytes of data. Right? So is this one really long document and gene editing is quite simply the ability to edit that [00:03:30] document. Speaker 3:It's like a cut and paste system, right? And a global global positioning system. Speaker 4:Yeah. What Dean editing lets you do is you can now go into this document and before all we could do is really read it. We could just know what was in it. But now with, with gene editing, we have the whole edit menu, right? So we can go to a location within the genome, we can cut out a sequence that we want to remove and then we can paste in a new sequence. So for example, if you have a, uh, a gene, uh, with a disease causing mutation in it, you [00:04:00] can cut that disease causing mutation out and then paste in a healthy gene. Speaker 3:Right. Okay. So it's, it's Kinda two parts, right? You know, you've got the, the CRISPR. Okay. And that stands for clustered regularly interspaced short palindromic repeats. Yeah, Speaker 4:it's a pretty, it's quite a mouthful. Basically what happens is that the bacteria would store this array of short sequences. That's the CRISPR array. And the sequences would match the sequences of the invading virus viral DNA, Speaker 3:so [00:04:30] that if it ever came again, it would recognize it. Speaker 4:Yeah. If the virus ever came back, it'd be like, oh, I know you. And then it would end the way that it recognizes the invading that DNA from its own DNA is because of, it's in this CRISPR array, it gets put onto the cas nine nucleus and the nucleus goes to the finding invading DNA and chops it up, but it won't chop up your own DNA because you don't have any of that sequence. You provide a guide, you have the cast nine nucleus and then you provide a guide, which is like a little RNA guide. It's an RNA guide. Yeah, we do it. We do it with RNA. Other [00:05:00] people can use RNA that's transcribed inside the cell. We actually provide the RNA outside the cell and put it right on the cas nine so RNA as a sequence, just like DNA. The sequence of the RNA can match a piece of DNA somewhere in the genome. So when you provide the guide and the CAS nine at the same time they get together and they go find the part of the genome that matches the sequence of the guide. So the guy guide has literally a guide Speaker 3:so you can program the guide to tell it where to go. Speaker 4:Exactly. So it's very, very easy to, to construct different SDR [00:05:30] and Aes, different guide rns to direct casts down to different places and in fact that's a major advantage of CRISPR cas nine technology over other gene editing technologies where they're not so easily repurposed to go after different targets. We've been doing gene editing for I think about 10 years in the old days, you know? Yeah. You'd have to do a lot approach in engineering. You have to synthesize a lot of different constructs, you know, different plasmids to continue to make different reagents, send them into cells and then pick the best one. It takes a lot of work, maybe a whole team of people, right? If you're working at a company that have like a whole team of people that do just [00:06:00] protein engineering, whereas mcast nine if I want to make a cas nine reagent that targets anywhere in the genome, I essentially order, I can order a template to make the RNA by typing it into the computer. A company sends it to me a day later. I can make you know, 10 different targets, hundreds of targets, right? People have done thousands or hundreds of thousands at once and then take that, make the RNA in my lab, mixed that with the protein in the night and introduce it into cells and generally almost all the cells get at it or they at least get the cut. The turnaround is, I mean I have my undergrads [00:06:30] doing it. I have visiting students doing it. I do it all the time. Speaker 3:What kind of oversight can anybody like? I can recreate the polio virus. Speaker 4:I can't just order a huge chunk of DNA that is big enough to encode an entire virus, Speaker 3:but are there other regulations on who can order what? Speaker 4:There are for sequences that contain toxins or infectious particles Speaker 3:like the polio or something like that, the whole polio virus. Speaker 4:And you're not allowed to order those synthetically. Or if you are, you have, you have to demonstrate that you have the qualifications [00:07:00] to work with that kind of genetic material. But you know, in our case we're going after genomes that are already there. So it's like your genome doesn't have any, you know, infectious particles in it. It has nothing contained in what we order that actually causes a disease. Okay. We're just going after disease genes that are already there. Okay. So in some senses it's actually much safer because there's no information that we're providing to the cells that could cause a disease unless we, you know, really want it to. Whereas for example, uh, the older version of gene therapy was to do viral delivery of [00:07:30] genes. And so since you're working with viruses, there's always risk of side effects. Even though the viruses are essentially de weaponized, there's still issues of where it puts the DNA, whether it could evolve into a different type of virus, these kinds of things. Speaker 3:Okay. You know who Hank Greely is at? Stanford law school. Oh, that sounds fun. Okay. He Dura, he's the director of the center for law and bio-sciences down there and he calls a the CRISPR cas nine the model t of bio-science. Hmm. Speaker 4:I guess what he's thinking is the model t was not the first car [00:08:00] or even the first car to be manufactured and just as that CRISPR cas nine is not the first gene editing technology. We've had it for some time, but it is the, it is the most robust and it's the easiest to work with. It's the one that everybody is out getting and trying and using. I mean not people that, not just people that specialize in gene in genomics or genetics, but really everybody. Yeah, and that sense it is the model t. It's the first one. It's the first version of this technology that everyone can use. What is the goal of it? Right off the bat, it is completely changed [00:08:30] the way that we do basic research. So, as I mentioned, it's very easy to work with now even if you're not a specialist in gene editing, but you have a, you know, a favorite gene that you like to, you want to characterize, you can target and manipulate that gene in human cells with such ease that you don't have to be a specialist and you can target many, many, many, many, many targets at once. Speaker 3:And so you in, in other words, like a goal of eradicating a certain that's heritable Speaker 4:[inaudible] well, so first is this used in basic research and then the other [00:09:00] potential application for CRISPR cas nine gene editing, early gene editing in general. And this is indeed already sort of underway, is m for gene therapy. As I mentioned, you know, you could have a genetic disease and then in some part of your body and then we can synthesize and inject reagents that will correct that mutation, fix the broken gene. And instead of, in the past we've been able to introduce genes into tissues, but only we can't fix a broken gene. Now we can actually go to the broken gene and replace it with healthy [00:09:30] sequence. Speaker 3:Okay, mark, let's break away for a minute and tell our audience they're listening to method to the madness here on k a l x Berkeley. Mark Dewitt is a postdoc over at the innovative genomics initiative at La caching center for Genomic engineering here at UC Berkeley. It sounds like you can do it one of two ways. You can go in and and fix an individual's broken chain system, or you can go in and correct it in embryonically and then it affects generations [00:10:00] later down the road Speaker 4:potentially. That's called germline editing and that's where you're editing the human germline. So that means that you create a heritable mutation in an embryo or probably a a fertilized embryo. Once you create that mutation or once you make that change, you know that that embryo will be implanted into a mother. She'll, uh, the baby will grow up, they'll have that change and then that, that kid will pass on that, that change to their kids. Most therapeutic applications of gene editing aren't really focused on that. Instead, [00:10:30] we're really focused on, and at the IGI we're only focused on, you know, editing healthy adults or sorry, adult patients. So it's just about the individual. And so in that case, when we make the edit, it's not transmitted to their progeny. So if you have a disease of your, so for example, I studied sickle cell disease, if I correct the sickle cell mutation inside your bone marrow, your bone marrow will be corrected and it'll be fixed, but your germline, your eggs or your sperm will not. Speaker 3:And we don't want it to be right because didn't it arise out of a resistance [00:11:00] to malaria thousands of years ago? To me, that's the issue of going after a germline. You don't know. That Speaker 4:raises the possibility that there could be unintended consequences of introducing things of introducing genetic alterations into the human germline. And that's absolutely true. And that's one reason why I think that, especially at this stage, it is just way too premature to undergo that kind of undertake that kind of research. The other issue is that it cuts at the place. You tell it to almost all the time, but sometimes it cuts other places. [00:11:30] That's called off target cutting. So it's not on your target, it's somewhere else. It's off your target. What's the success rate? Usually though the frequency of off target cutting is, it depends on the application. It's usually on the order of 1% or less. So it's too bad. Yeah. But if you have 4 trillion cells, a substantial number of cells in a gene edited individual. So if one of those off target cuts causes a nasty side effect, like for example, it knocks out a gene that's supposed to protect [00:12:00] yourselves from cancer, but then you could, all it takes is one cell to be edited to be edited in that manner. This unintended manner to cause the cancer. Speaker 3:Weren't you in a paper recently? I think nature biotechnology where you guys came up with a bubble technique that avoids cutting. Speaker 4:Yes. So one way to avoid off target cutting is to just don't cut it all. What we found in that paper was is that if you use a a cast nine that doesn't cut it simply can't cut it all. It still creates a structure, DNA protein structure that is accessible to the [00:12:30] replacement sequence you're trying to provide. It's not nearly efficient enough to really drive the kinds of levels of editing that would be relevant. You can think of it as DNA has two strands, the famous double helix. What we found is as the task then goes and pries open those two strands and clamps really hard on one of the strands, but then the other strand is essentially released and is free and so if you provide a sequence of DNA that binds to that strand, it will get incorporated. Now you've opened it up, you can stick stuff onto it. The advantage [00:13:00] of that technique is that you get no, is that since there's no cutting, the chances of off target activity are vastly reduced. Speaker 3:Are you primarily working on sickle cell? Speaker 4:So sickle cell disease is a disease of your red blood cells and you know, we've known about the genetics and the molecular basis of the disease. For almost 70 years. I mean it's one of the oldest, it's the oldest genetic disease that we know about and it was the first genetic disease to truly be characterized. I mean right around the time we discovered the structure of DNA, [00:13:30] we were already figuring out how sickle cell, Speaker 3:right and it's a defect in only one gene, which is very different from a lot of other diseases. Speaker 4:Exactly. So we call that monogenetic versus poly genetic. It's a moto genetic disease and that it has exactly one cause and in fact that's all the way down to the molecular level. There is a single letter or a single base pair change in your genome that causes the disease. And so that change is in this gene called Hemoglobin Beta, which is one of the two proteins that make up hemoglobin, which is what makes your red blood cells red. [00:14:00] It's what carries oxygen, you know, from your lungs to the rest of your tissues. It's all going through this hemoglobin protein, hemoglobin protein that has this sickle cell mutation will aggregate inside the south, will form these long, these big clumps inside your red blood cells. And these clumps cause the cells to become deformed and adopt that, that this characteristic sickle cell. Yeah. It's more like a crescent moon. Speaker 4:I mean we're not farmers anymore. So I figured, yeah, we should update the language, but I sip like a crescent moon or a sickle. The sickle RBCs [00:14:30] well, first off, they're not as effective at carrying oxygen. So you have anemia, but also they can clog blood vessels and like your capillaries, they won't fit in your capillaries very well and that can damage the capillaries and also can lead to these crises where your blood vessels get clogged. So it causes that increased risk of stroke and pulmonary hypertension and also the damage to your blood vessels can cause organ failure. So it's a progressive disease in the sense that individuals in, in countries with developed health systems like the United States, their symptoms aren't very [00:15:00] severe and they're very manageable for the first few years of life. But then as they get older and older and older, um, increasingly severe symptoms will manifest. Speaker 4:And ultimately it leads to something like a 25 to 30 year detriment in lifespan. And it's an inherited disease, inherited disease, and we have two copies of every gene, right? Individuals that have one copy of this, of this mutation. So they have a mutated gene and the healthy gene are called carriers and they also have this clinical presentation is called from sickle cell trait and individuals with sickle cell trait [00:15:30] are generally healthy and also have some resistance to malaria. And that's how the, that's how this mutation is maintained in the populations in, in populations and malarial regions to Subsaharan Africa and southern India where the mutation first arose. The United States is not a malarial country, but of course we have a large minority of African Americans whose genetic heritage is from Subsaharan Africa from these regions. And that's why sickle cell disease, which is when you have both of your genes have the mutation in America is found [00:16:00] almost entirely in the African American population. Speaker 4:So about a hundred thousand Americans, again, almost all African American had the disease in the country as a whole and I think 10,000 in California. So it's actually quite a lot of people close. Are you to a cure? I'd like to think we're pretty close. We, we, we haven't moved towards the clinic yet. I'm hoping that one of us will be able to start trials within the next two or three years. But there are other strategies for treating sickle cell disease that are more indirect, that are already in clinical trials using gene editing. [00:16:30] How are those different from what you're doing or our approach at IGI is to directly correct the mutation so we know exactly where the mutation is and we've known it for 70 years. But as I mentioned, just because you know where something is in the word document doesn't mean you could fix it until now. Speaker 4:What our approach is is to make a cut at the mutation and then supply replacement sequence. The replacement sequence is a short piece of DNA. So in order to cause a lasting alteration to your, to the genetics of your blood cells, we actually have to edit your bone marrow cells. [00:17:00] So we take bone marrow cells from patients that have sickle cell disease and then we, this is all in the labs. So we're working this Albridge called ex Vivo or in the lab we cut at the [inaudible] at the mutated region using cas nine and then we supply a short piece of DNA that has the corrected sequence in it. So it just doesn't have any grow. Yeah. And so that will get incorporated in some fraction of the cells. We generally get about 20 to 30% in view in vitro. Then you let the cells grow, then we just analyze them. Speaker 4:So we'll differentiate them into red blood cells and see if they still have sickling [00:17:30] properties. We'll look at their, their gene expression, um, viability, all sorts of, you know, in vitro and points. The other thing we do is that we will edit the cells and inject them into a mouse carrier where the cells will live for months and months and months and then take the cells out of the mouse four months later to see if they still have enough editing to cure the disease. And so none of this goes back into people. Now, the way it would eventually work, if you actually were doing this in a clinical setting, is that you would take a fraction of a patient of a sickle patients bone marrow. You would correct [00:18:00] it using the same exact technique that we're using, but at a much, much larger scale, like we're doing a hundred thousand to a million cells. Speaker 4:You'd be doing more like a billion cells. You would correct the cells, culture them for a day or two in an incubator and then pull them back together and reinfuse them into the patient. Now meanwhile, you would be ablating the patient's bone marrow are using chemotherapy. You can't avoid that. No. What we're hoping is is that if the editing is efficient enough, you don't have to completely ablate the bone marrow, so you don't, you can use a lighter course of chemotherapy, [00:18:30] but you still have to use a certain amount of chemotherapy to get rid of all the remaining uncorrected bone marrow that we just don't have the ability to, to correct that many cells at once. It's just the scale is not practical. So most, um, applications for now for gene editing or gene therapy in general, whether using viruses or, or CRISPR, cas nine or anything else, uh, they generally do this chemotherapy step. Speaker 4:There are many, many groups working on noninvasive methods to do gene editing. So one is to inject a virus that contains [00:19:00] all the stuff you need to make the edit into straight into the compartment that you're trying to treat. So in this case, it would be the, you inject the reagent into the bone marrow, which is painful, but it's a lot better than chemotherapy. Right? Virus is sort of nature's oldest nanoparticle. It's very good at finding cells and putting stuff inside of them. I think we can do better. We can engineer synthetic particles that can do all the same things. They can find the target cell, in this case, a bone marrow stem cell, the cell that leads to all of your other blood cells and they can find them. [00:19:30] And then they can inject all the reagents into that cell specifically and they'll go in and make the edit while the bone marrow cells are still inside your bones. Speaker 4:Um, and that's called Invivo gene editing and that's still very, very much in the early stages. But you know, whether using a viral technique or a nanoparticle technique, you know, from what I've seen in the literature, it's probably only a matter of time. It could be 20 years, it could be 30 years, but you know, it's only a matter of fact. Well, I mean in medical biomedical terms, that's pretty short. You know, when you read the articles, I mean this stuff is all [00:20:00] over the media now and it just sounds so exciting. Like in a couple of years, everything's going to be, these technologies take a very, very, very long time to perfect and try and then get through FDA approval and so on and so forth. A lot of that is just that it takes a lot of time to iron out all of the kinks and biotech. Speaker 4:But what about in other countries won't develop countries? They still don't, they still don't exactly move very quickly. First off, it's hard to prove efficacy. Sometimes it's hard to show that your treatment is actually being effective and you need to try [00:20:30] it. On a whole bunch of people in a whole bunch of different settings and for a whole bunch of reasons and that's just never not going to be really expensive to get the numbers you need to show that something's effective, whether you're the FDA, FDA or anybody else. It's a very expensive process. Getting enough statistical power to do that. You're still talking or thousands of people that you have to test it on and the process is lengthy and expensive. But you know, in my opinion, I think that's all well and good that we have that level of oversight, but it doesn't mean that things take years to really come to fruition and maybe maybe gene editing [00:21:00] might be a little quicker. Speaker 4:There's a lot of very specific problems associated with viral techniques that hopefully we won't have for our approach. I wouldn't be surprised if it took another five or 10 years to really get all the, get all the kinks ironed out. So down the road, what are some of the goals of this research? Monogenetic diseases like sickle cell. The second goal is poly genetic diseases. So this is sort of more of a pie in the sky idea here. We're just beginning to uncover that there are significant genetic contributions to non genetic diseases [00:21:30] to the chances of coming down with a non genetic disease. And I'm speaking specifically about Parkinson's and Alzheimer's. And so we found that there are certain mutations that we're not exactly sure why the sudden mutations that appear to increase your susceptibility to the disease or decrease your subset susceptibility to the disease. Speaker 4:And so that provides a handle for researchers to determine whether or not there is a sort of silver bullet genetic solution to actually curing this disease so that the [00:22:00] patients with these mutations or individuals with these mutations have almost no chance of getting Alzheimer's. Does that mean if I take a person who is, um, coming down with or starting to show signs of Alzheimer's or is at a high risk of Alzheimer's and I introduce this mutation into their, you know, into their tissues, you know, would that cure the disease? Would that essentially short circuit? Would that beat out whatever factors are making them get the disease by providing a different mutation entirely. How do you make that mutation in cells? Well, you should use gene [00:22:30] editing and then make the mutation and then see if all things being equal, that mutation alone can confer resistance to the Alzheimer's phenotype. Speaker 4:That'd be pretty exciting. It is very exciting. So I really think that, I guess as a gene editor or as a hammer looking for a nail, there are a lot more nails, especially in America, developed health system that are non genetic diseases. Are you from California? No, I'm from Boston. Where did you go undergrad? Um, I went to Undergrad at this small liberal arts college [00:23:00] in Portland called Reed College. It's, it's a, it's a fascinating place. Some enormous percentage of Reed college graduates go on to get PhDs. And so after I finished at Reed, I was there for a couple of years and he came down here to get my phd and I stayed on for my postdoc. Now my phd was in something completely different than what I do biophysics. And specifically I studied, um, these proteins that carry materials around your cells called motor proteins. My entire phd was, you imagine a bunch of white dots [00:23:30] on a computer screen moving across the screen, like in a straight line. Speaker 4:That's what I did. I looked at these dots and looked at how fast they're moving. And so I did that for about seven years. And then I just, you know, went to this seminar here, actually the first rewriting genome seminar. It was a, it was a seminar organized by Jennifer Doudna and it had all of the top investigators in gene editing at the time. So I went to the seminar. I was just blown away. I was like, this is so cool. This is just the coolest thing ever. Right? Like I have to do this. I emailed Jennifer, who [00:24:00] is in my building, my old building, Stanley Hall up the hill from here. I'd heard that she was trying to set up this, this organization, this, um, initiative to explore the applications of CRISPR cas nine, whereas her lab is focused on the, the core technology itself, making the technology better. Speaker 4:We would be taking those kinds of innovations and the innovations of others and using it to find applications. Right. And so I was more interested in that, partly strategically thinking, you know, we're going to get past the developing the technology [00:24:30] part pretty soon, but we're going to be exploring applications for hopefully the rest of our careers. So, you know, I thought that was a good decision for a lot of reasons. And so I talked to Jennifer and she said, oh yeah, like yeah, I'm doing it. We need postdocs. She could put me in touch with Jacob Korn, who's the director of IGI who hadn't formally joined yet. Speaker 2:And IGI is again Speaker 4:the innovative genomics initiative. The research lab is about 15 people. It's going to get a little bit bigger and then, but as you had just lots of other stuff, IGI also does some outreach. [00:25:00] The most inefficient thing we've done yet is we host a workshop. So we invite scientists from all around the community, ideally scientists that don't work in the field of gene editing, but want to try it out. Not just scientists or doctors, but also, you know, policymakers. And Speaker 2:there is a reason to make sure that it stays in the right hands. Yes there is. Does anything scare you about it at all? I mean, you're right in the heart of it, Speaker 4:you know, you think of bad actors and things like that. Although again, whether we're happy about it [00:25:30] or not, humanity has invented a whole host of really dangerous bad things from nuclear weapons to infectious agents to chemical weapons, weapons of mass destruction. And you know, we're all still here. It's, I guess what I mean. Should there be any controls on the use of the technology for research compared to other technologies like I don't think so. Should we be very careful about, well, what if someone wanted to do something not so good with this method that I'm outlining in publishing in a paper, [00:26:00] right? I mean, yes, we should. And that's exactly why we, I think should be very careful about germline editing. And again, that's why at IGI we're really focused on more traditional therapeutic editing. Speaker 2:Yeah, you're lucky that Jennifer is a big part of that because you know, she is a vocal person about the ethics involved. Here's a short segment from a Ted talk that she gave recently. Together with my colleagues, I've called for a global conversation about the technology that I co-invented so that we can consider all of the ethical [00:26:30] and societal implications. Imagine that we could try to engineer humans that have enhanced properties such as stronger bones or less susceptibility to cardiovascular disease, good eye color, or not to be taller designer humans, if you will. Right now, the genetic information to understand what types of genes would give rise to these traits are mostly not known, but it's important to know that the CRISPR technology gives us a tool to make such [00:27:00] changes. Once that knowledge becomes available, this raises a number of ethical questions that we have to to carefully consider. Speaker 2:This is why I and my colleagues have called for a global pause in any clinical application of the CRISPR technology in human embryos to give us time to really consider all of the, the various implications of of doing so. This is no longer science fiction, genome engineered animals and plants are happening right now. And this puts in front of all of us [00:27:30] a huge responsibility to consider carefully both the unintended consequences as well as the intended impacts of a scientific breakthrough. So mark, what would you like to see happen in this space in the near future? Speaker 4:Suddenly, I'm thinking about a lot lately is that this idea of personalized gene editing. You can imagine a world in which you go into the doctor, they sequence your genome, they see if there's anything that needs fixing [00:28:00] and then they put it in order for the reagent that can be synthesized custom to whatever specifications. So it can go into whatever Oregon you want, whatever cell type you want and program any genetic change you want based on your own genetic sequence. You then go into the doctor's office and they put something into your arm and they infuse you with that reagent and then it starts to make the change. It's certainly our approach with sickle cell, you know, points in that direction. The reasons that we're using are simple. They're easily customizable. [00:28:30] Um, you don't have to have a lot of it on hand. You can produce it in a factory instead of having to grow it from cell culture. Speaker 4:I imagine that future, this far off future in which we have sort of live in this almost Saifai type world where you know, you can make any genetic manipulation you want or your doctor candidly, you know, in the doctor's office, no surgery, no surgery, no nothing. Well then I think about, so what am I doing today that's going to nudge the, the rock a little bit further up the hill in that direction? Where do I want things to be in 20 years and what can I do [00:29:00] to go there? We'll see how I do, right? I mean, I'm still just a postdoc, but I think it really, really helps to think about like what's the La crazy, crazy far off like vision for what you're doing? Like how, how could it totally change the world? And it's important to think about that when you're at the lab bench. Speaker 4:You know, whether you're in a classroom lab at bio one a or whether you're in my research lab, what am I doing to bring that out? That longterm vision. It's so easy to lose track [00:29:30] of where you're going in the day to day, especially as a scientist, because as researchers we have, our head is filled with innumerable minutiae of our day to day experiments that just all we ever think about, and sometimes you need to step back and be like, what am I really doing? That's a characteristic, certainly of the most successful entrepreneurs and probably the most successful scientists as well. Speaker 3:Well, mark, you've helped us understand some very complicated ideas. I've been talking with Mark Dewitt. He is a biophysicist and a lab member of the innovative genomics [00:30:00] initiative here on campus at Lee Kushing center for Genomic Engineering. Thanks again for being on this program and talking about a very difficult and complex subject of gene editing. Thanks for having me. You've been listening to method to the madness. We'll be back again in two weeks is the same. I'm Speaker 1:telling you. See acast.com/privacy for privacy and opt-out information.

Temple University Men's Gymnastics Coach, Fred Turoff (left). NCAA Judge, Dean Ratliff (top). NCAA recruiting expert, Jill Hicks.   An all interview show with three NCAA guests! First we talk to NCAA Judge Dean Ratliff. We discuss: How judges are reviewed, assigned and favoritism curtailed in the NCAA. The weirdest and wildest things Dean has seen during his 28 years of judging high school and NCAA meets. How judges are assigned to judge NCAA gymnastics meets. The continual, meteoric rise in scores from the top 36 college gymnastics teams. How much puppy-mill-style-factory-farm-mega-meets suck for judges, parents and kids. What Dean thinks of Jessica's genius idea that judges should score live on an iPad and give the audience (the fans!) access to the scoring sheets after each routine. How judges address accusations of bias bias bias and more bias. Next up is former US national team member, occasional USAG selection committee member and long-time coach of the Temple University Owls, Fred Turoff. Last week, the Philadelphia institution announced they were dropping seven of their 24 sports, including men's gymnastics.  Coach Turoff told us the despicable details including: The way Temple University told student athletes that their sports were being dropped the Friday before finals week. The impact Temple's disappearance could have on all of men's gymnastics, NCAA gymnastics and by extension Team USA. How the committee who made the cuts met in secret over months to avoid allowing the coaches to appeal to the Board of Trustees, which they had done successfully in 1994 when the program was threatened. What you can do to help the program survive. Next we talk with, NCAA recruiting expert, Jill Hicks. She did a survey of coaches to find out what they thought about the scourge that is early recruiting. We discuss: If early recruiting can be stopped Advice for recruits and their parents on how to avoid being pressured into committing early. The best way for coaches and gym owners to get their gymnasts recruited The new sport that is recruiting gymnasts for college scholarships (It's not cheerleading! Sheesh. Do you seriously think we'd talk about it, if it was? Come on people. The episode also features the greatest Gymnastics Myth Busters in the history of the show! We find out if these statements are true or false: There was a gymnast-streaker at an NCAA championships. It is possible to accidentally hang upside down by a jock strap from high bar. Make-up, facial jewelry, mohawks and painted nails are prohibited. Judges can take artistry and vulgarity deductions. Judges can stop a gymnast from performing a skill that is too dangerous. Olympians and gymnasts from the top teams, receive "status" bonuses. Contact Fred Turoff to find out what you can do to help save the men's gymnastics program. Here is our ranking of gymnastics schools with the best recruiting pages for their gymnasts: Wildfire Olympus (includes GPA's for each athlete) Illinois Gymnastics Institute College scholarships opportunities for gymnasts in the sport of Tumbling & Acrobatics, governed by the NCATA. They get to wear cool uniforms like the University of Oregon team. Judge Ratliff is the Technical Director of the National High School Gymnastics Association. Find out about the Senior Showcase Invitational in Florida here Our hero, (above) the woman who brought the dangers of face sparkles to the fore, Oregon State's, Kelsi Blalock of skin-bling meets balance beam face. We thank you for your service and courage Miss Blalock! *gymternet salute* Judge Ratliff refers to this type of jewelry in his interview. This is what a ear gage or plug looks like.  

Posted in BlogPodcast Play Audio How to use ‘brand’ the smart way Lessons from General Patton 6 questions James uses to turn skeptical prospects into satisfied customers What Dean uses to recognize 5-star prospects The ‘Just Level With Me’ technique that gets prospects to reveal exactly what you need to make sales Dean describes the best membership program that keeps members forever Download MP3